20705401|t|Serotonin 6 receptor gene is associated with methamphetamine-induced psychosis in a Japanese population.
20705401|a|BACKGROUND: Altered serotonergic neural transmission is hypothesized to be a susceptibility factor for psychotic disorders such as schizophrenia. The serotonin 6 (5-HT6) receptor is therapeutically targeted by several second generation antipsychotics, such as clozapine and olanzapine, and d-amphetamine-induced hyperactivity in rats is corrected with the use of a selective 5-HT6 receptor antagonist. In addition, the disrupted prepulse inhibition induced by d-amphetamine or phencyclidine was restored by 5-HT6 receptor antagonist in an animal study using rats. These animal models were considered to reflect the positive symptoms of schizophrenia, and the above evidence suggests that altered 5-HT6 receptors are involved in the pathophysiology of psychotic disorders. The symptoms of methamphetamine (METH)-induced psychosis are similar to those of paranoid type schizophrenia. Therefore, we conducted an analysis of the association of the 5-HT6 gene (HTR6) with METH-induced psychosis. METHOD: Using five tagging SNPs (rs6693503, rs1805054, rs4912138, rs3790757 and rs9659997), we conducted a genetic association analysis of case-control samples (197 METH-induced psychosis patients and 337 controls) in the Japanese population. The age and sex of the control subjects did not differ from those of the methamphetamine dependence patients. RESULTS: rs6693503 was associated with METH-induced psychosis patients in the allele/genotype-wise analysis. Moreover, this association remained significant after Bonferroni correction. In the haplotype-wise analysis, we detected an association between two markers (rs6693503 and rs1805054) and three markers (rs6693503, rs1805054 and rs4912138) in HTR6 and METH-induced psychosis patients, respectively. CONCLUSION: HTR6 may play an important role in the pathophysiology of METH-induced psychosis in the Japanese population.
20705401	0	20	Serotonin 6 receptor	GeneOrGeneProduct	3362
20705401	45	60	methamphetamine	ChemicalEntity	D008694
20705401	69	78	psychosis	DiseaseOrPhenotypicFeature	D011605
20705401	208	227	psychotic disorders	DiseaseOrPhenotypicFeature	D011605
20705401	236	249	schizophrenia	DiseaseOrPhenotypicFeature	D012559
20705401	255	283	serotonin 6 (5-HT6) receptor	GeneOrGeneProduct	3362
20705401	341	355	antipsychotics	ChemicalEntity	D014150
20705401	365	374	clozapine	ChemicalEntity	D003024
20705401	379	389	olanzapine	ChemicalEntity	D000077152
20705401	395	408	d-amphetamine	ChemicalEntity	D003913
20705401	417	430	hyperactivity	DiseaseOrPhenotypicFeature	D006948
20705401	434	438	rats	OrganismTaxon	10116
20705401	480	505	5-HT6 receptor antagonist	ChemicalEntity	D012702
20705401	565	578	d-amphetamine	ChemicalEntity	D003913
20705401	582	595	phencyclidine	ChemicalEntity	D010622
20705401	612	637	5-HT6 receptor antagonist	ChemicalEntity	D012702
20705401	663	667	rats	OrganismTaxon	10116
20705401	741	754	schizophrenia	DiseaseOrPhenotypicFeature	D012559
20705401	801	816	5-HT6 receptors	GeneOrGeneProduct	3362
20705401	856	875	psychotic disorders	DiseaseOrPhenotypicFeature	D011605
20705401	893	908	methamphetamine	ChemicalEntity	D008694
20705401	910	914	METH	ChemicalEntity	D008694
20705401	924	933	psychosis	DiseaseOrPhenotypicFeature	D011605
20705401	958	985	paranoid type schizophrenia	DiseaseOrPhenotypicFeature	D012563
20705401	1049	1054	5-HT6	GeneOrGeneProduct	3362
20705401	1061	1065	HTR6	GeneOrGeneProduct	3362
20705401	1072	1076	METH	ChemicalEntity	D008694
20705401	1085	1094	psychosis	DiseaseOrPhenotypicFeature	D011605
20705401	1129	1138	rs6693503	SequenceVariant	rs6693503
20705401	1140	1149	rs1805054	SequenceVariant	rs1805054
20705401	1151	1160	rs4912138	SequenceVariant	rs4912138
20705401	1162	1171	rs3790757	SequenceVariant	rs3790757
20705401	1176	1185	rs9659997	SequenceVariant	rs9659997
20705401	1261	1265	METH	ChemicalEntity	D008694
20705401	1274	1283	psychosis	DiseaseOrPhenotypicFeature	D011605
20705401	1284	1292	patients	OrganismTaxon	9606
20705401	1412	1427	methamphetamine	ChemicalEntity	D008694
20705401	1439	1447	patients	OrganismTaxon	9606
20705401	1458	1467	rs6693503	SequenceVariant	rs6693503
20705401	1488	1492	METH	ChemicalEntity	D008694
20705401	1501	1510	psychosis	DiseaseOrPhenotypicFeature	D011605
20705401	1511	1519	patients	OrganismTaxon	9606
20705401	1715	1724	rs6693503	SequenceVariant	rs6693503
20705401	1729	1738	rs1805054	SequenceVariant	rs1805054
20705401	1759	1768	rs6693503	SequenceVariant	rs6693503
20705401	1770	1779	rs1805054	SequenceVariant	rs1805054
20705401	1784	1793	rs4912138	SequenceVariant	rs4912138
20705401	1798	1802	HTR6	GeneOrGeneProduct	3362
20705401	1807	1811	METH	ChemicalEntity	D008694
20705401	1820	1829	psychosis	DiseaseOrPhenotypicFeature	D011605
20705401	1830	1838	patients	OrganismTaxon	9606
20705401	1866	1870	HTR6	GeneOrGeneProduct	3362
20705401	1924	1928	METH	ChemicalEntity	D008694
20705401	1937	1946	psychosis	DiseaseOrPhenotypicFeature	D011605
20705401	Association	rs4912138	D011605	Novel
20705401	Association	rs4912138	D008694	Novel
20705401	Association	rs1805054	D011605	Novel
20705401	Association	rs1805054	D008694	Novel
20705401	Association	rs6693503	D011605	Novel
20705401	Association	rs6693503	D008694	Novel
20705401	Association	D010622	D012702	No
20705401	Association	D012702	D012559	No
20705401	Association	D003913	D012702	No
20705401	Positive_Correlation	D003913	D006948	No
20705401	Association	3362	D000077152	No
20705401	Association	3362	D003024	No
20705401	Association	3362	D014150	No
20705401	Association	3362	D006948	No
20705401	Association	3362	D011605	Novel
20705401	Association	3362	D008694	Novel
20705401	Negative_Correlation	D011605	D000077152	No
20705401	Negative_Correlation	D011605	D003024	No
20705401	Positive_Correlation	D008694	D011605	No